Abstract: The present disclosure relates to methods of modulating level of pathogenic E. coli (EHEC, EPEC, APEC) present in the gastrointestinal tract of an animal by administering saccharide compositions comprising an anhydro moiety. The presence/load with pathogenic E. coli strains can be assessed via the level of LEE and non-LEE pathogenic genes in the microbiome of the host animal.

Abstract: The present disclosure relates to methods of feeding animals by providing feed additives that modulate the gut microbiome improve the health and welfare of the animal. The present disclosure further relates to methods of modulating level of secondary metabolites present in the gastrointestinal tract of an animal. Such modulation includes, for example, modulating the level of tryptophan metabolism derivates.

Abstract: The present disclosure relates to methods of modulating level of E. coli present in the gastrointestinal tract of an animal. Such modulation includes, for example, modulating the level of LEE and non-LEE pathogenic genes in the microbiome of the host animal. The present disclosure further relates to methods of modulating the virulence of pathogenic E. coli in the gastrointestinal tract of an animal by reducing the population of B. thetaiotaomicron in the gut microbiome of the animal.

Abstract: The present disclosure relates to methods of feeding animals by providing feed additives that modulate the gut micro-biome improve the health and welfare of the animal. The present disclosure further relates to methods of modulating level of secondary metabolites present in the gastrointestinal tract of an animal. Such modulation includes, for example, modulating the level of tryptophan metabolism derivates.

Abstract: The present disclosure relates to methods of feeding animals by providing feed additives that modulate the gut microbiome to improve the health, nutrition, and growth performance. The present disclosure further relates to methods of modulating metabolites present in the gastrointestinal tract of an animal. Such modulation includes, for example, modulating the level said metabolites.

Abstract: The present disclosure relates to methods of feeding animals by providing feed additives that modulate the gut microbiome to improve the health, nutrition, and growth performance. The present disclosure further relates to methods of modulating the microbial species present in the gastrointestinal tract of an animal. Such modulation includes, for example, modulating the level or function of microbial species.

Abstract: The present disclosure relates to methods of feeding animals by providing feed additives that modulate the gut microbiome to improve the health, nutrition, and growth performance. The present disclosure further relates to methods of modulating metabolites present in the gastrointestinal tract of an animal. Such modulation includes, for example, modulating the level said metabolites.

Abstract: In some aspects, the disclosure is directed to methods and systems for identifying a set of predictor metabolites which are predictive of a state of an animal subject. For that purpose, a plurality of data sets of respective ones of a plurality of animal subjects may be obtained, wherein each of the plurality of data sets comprises measurement data comprising an indication of a concentration of each of a plurality of metabolites in a sample of a microbiome of a respective animal subject. A label may be provided at least in part characterizing the state of the animal subject. A feature selection process may be applied to the plurality of data sets to select and thereby identify a subset of the plurality of metabolites of which subset the concentrations are a statistically significant predictor of the state according to the label.

Abstract: The present disclosure relates to methods of feeding animals by providing feed additives that modulate the gut microbiome to improve the health, nutrition, and growth performance. The present disclosure further relates to methods of modulating metabolites present in the gastrointestinal tract of an animal. Such modulation includes, for example, modulating the level said metabolites.

Abstract: The present disclosure relates oligosaccharide preparations suitable for use in nutritional compositions such as animal feed and methods of manufacturing the described oligosaccharide preparations. The present disclosure further relates to nutritional compositions that comprise the oligosaccharide preparations. The disclosed oligosaccharide preparations can be advantageous as an animal feed due to, at least in part, their prebiotic utility and the presence of anhydro-subunit containing oligosaccharides, which can be used to detect and/or determine the presence and content of the disclosed oligosaccharide preparations in the nutritional composition.

Abstract: A method for visualizing microbiome data is described. Respective microbes and/or genes in microbiome data stored In in a database are identified. A network comprising nodes interconnected by edges is generated in a memory of a computer, each node representing one or more identified microbes or one or more microbial metabolites, and each edge of the network representing an association between a respective pair of the one or more identified microbes or a reaction mediated between two metabolites by an enzyme encoded in the one or more identified genes, with at least some nodes and edges of the network being each associated with a condition attribute identifying a groups and/or a timestamp associated with a sample in the database. The displayed network is dynamically updated in accordance with a filtering of the microbiome data based on the condition attributed and/or the timestamp attributed. Corresponding systems and computer-readable storages are also described.

Abstract: The present disclosure relates to methods of feeding animals by providing feed additives that modulate the gut microbiome to improve the health, nutrition, and growth performance. The present disclosure further relates to methods of modulating metabolites present in the gastrointestinal tract of an animal. Such modulation includes, for example, modulating the level said metabolites.

Abstract: The invention involves mutant genes that enable a Bacillus or other bacterial strain, such as Bacillus subtilis or B. licheniformis strain to overproduce acids. These genes can be inserted into a suitable strain and the resulting mutant strain can be used as a probiotic, preferably for use in animal health.

Abstract: The present disclosure relates to methods of feeding animals by providing feed additives that modulate the gut microbiome to improve the health, nutrition, and growth performance. The present disclosure further relates to methods of modulating the microbial species present in the gastrointestinal tract of an animal. Such modulation includes, for example, modulating the level or function of microbial species.

Abstract: The present disclosure relates oligosaccharide preparations suitable for use in nutritional compositions such as animal feed and methods of manufacturing the described oligosaccharide preparations. The present disclosure further relates to nutritional compositions that comprise the oligosaccharide preparations. The disclosed oligosaccharide preparations can be advantageous as an animal feed due to, at least in part, their prebiotic utility and the presence of anhydro-subunit containing oligosaccharides, which can be used to detect and/or determine the presence and content of the disclosed oligosaccharide preparations in the nutritional composition.

Abstract: Fusion-proteins containing an enzyme, preferably a feed or food enzyme, coupled to a gut surface-binding domain are presented. The fusion-proteins can be used to promote feed utilization in animals. In a particular example, a Fusion enzyme according to the invention comprising a gut-surface-binding polypeptide segment linked to a phytase show an increased resident time in the gut, which leads to an increased amount of time given to the enzyme to catalyse the corresponding reaction which finally leads to improved feed utilisation.

Abstract: Fusion-proteins containing an enzyme, preferably a feed or food enzyme, coupled to a gut surface-binding domain are presented. The fusion-proteins can be used to promote feed utilization in animals. In a particular example, a Fusion enzyme according to the invention comprising a gut-surface-binding polypeptide segment linked to a phytase show an increased resident time in the gut, which leads to an increased amount of time given to the enzyme to catalyse the corresponding reaction which finally leads to improved feed utilisation.

Abstract: This invention discloses novel bacterial spore systems. Genetically modified or genetically engineered viable spore systems expressing bioactive polypeptides, for example bacteriocins and/or enzymatically active feed enzymes, at the spore surface, have a great potential use in animal feeding. Genetically modified or “genetically engineered inert spore systems expressing affinity ligands or immobilized enzymes at the surface have a great potential use in biocatalysis and in the construction of biocatalytic films. Especially the resistance to harsh chemicals, desiccation, strong pressure, or high temperatures allows the spores to be a potentially valuable tool for the display of bioactive molecules, like biocatalytic enzymes or bioactive feed enzymes that must survive harsh conditions to deliver their full potential.

Abstract: The present invention relates to the display of bioactive molecules at the surface of spores for both in vitro and in vivo applications. Three small open reading frames (ORFs) have been identified which are very useful for display of bioactive molecules at the spore surface. The encoded small proteins have a molecular weight of less than 12 kDa, which corresponds to about less than 100 amino acids.

Abstract: The present invention provides a method for producing thiamin products using a microorganism containing a mutation that causes it to overproduce and release thiamin products into the medium. Biologically pure cultures of the microorganisms and isolated polynucleotides containing the mutations are also provided. In addition, methods for detecting a pathogenic microorganism in a clinical sample, assays for identifying an antibiotic, as well as, antibiotics identified by such assays are provided.